Evidence map›Paper›PMID 35206278›Full record

ArticleInternational journal of environmental research and public health2022

ARNI in HFrEF-One-Centre Experience in the Era before the 2021 ESC HF Recommendations.

Rafał Niemiec, Irmina Morawska, Maria Stec, Wiktoria Kuczmik, Andrzej S Swinarew, Arkadiusz Stanula, Katarzyna Mizia-Stec

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Rafał NiemiecUpper Silesian Medical Centre, First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, 40-055 Katowice, Poland.ORCID 0000-0002-0411-5011
Irmina MorawskaUpper Silesian Medical Centre, First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, 40-055 Katowice, Poland.ORCID 0000-0003-2014-6771
Maria StecUpper Silesian Medical Centre, Students' Scientific Society of the First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, 40-055 Katowice, Poland.
Wiktoria KuczmikUpper Silesian Medical Centre, Students' Scientific Society of the First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, 40-055 Katowice, Poland.
Andrzej S SwinarewFaculty of Computer Science and Material Science, Institute of Material Science, University of Silesia in Katowice, 40-055 Katowice, Poland.ORCID 0000-0001-6116-9510
Arkadiusz StanulaInstitute of Sport Sciences, The Jerzy Kukuczka Academy of Physical Education, 40-065 Katowice, Poland.ORCID 0000-0003-1759-6456
Katarzyna Mizia-StecUpper Silesian Medical Centre, First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, 40-055 Katowice, Poland.ORCID 0000-0001-6907-2799
Medical University of Silesia · PLAkademii Wychowania Fizycznego im. Jerzego Kukuczki w Katowicach · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has demonstrated a survival benefit and reduces heart failure hospitalization in patients with heart failure with reduced left ventricular ejection fraction (HFrEF); however, our experience in this field is limited. This study aimed to summarize a real clinical practice of the use of ARNI in HFrEF patients hospitalized due to HFrEF in the era before the 2021 ESC HF recommendations, as well as assess their clinical outcome with regard to ARNI administration. METHODS AND MATERIALS: Overall, 613 patients with HFrEF hospitalized in 2018-2020 were enrolled into a retrospective one-centre cross-sectional analysis. The study population was categorized into patients receiving (82/13.4%) and not-receiving (531/82.6%) ARNI. Clinical outcomes defined as rehospitalization, number of rehospitalizations, time to the first rehospitalization and death from any cause were analysed in the 1-2 year follow-up in the ARNI and non-ARNI groups, matched as to age and LVEF.

resultsClinical characteristics revealed the following differences between ARNI and non-ARNI groups: A higher percentage of cardiovascular implantable electronic devices (CIED) (

conclusionsOur current positive experience in ARNI therapy is limited to extremely severe patients with HFrEF. Regardless of the more advanced HF and HF comorbidities, the patients treated with ARNI presented similar mortality and rehospitalizations as the patients treated by standard therapy.

Indexed as

AminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsHeart FailureValsartanVentricular Dysfunction, LeftCross-Sectional StudiesDrug CombinationsHumansRetrospective StudiesStroke VolumeTreatment OutcomeVentricular Function, LeftAminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug CombinationssacubitrilValsartanARNIheart failureheart failure with reduced left ventricular ejection fractionHFHFrEFsacubitril/valsartan

Identifiers

PMID35206278
PMCPMC8872461
OpenAlexW4212931124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.